• Henrique B Ribeiro, John G Webb, Raj R Makkar, Mauricio G Cohen, Samir R Kapadia, Susheel Kodali, Corrado Tamburino, Marco Barbanti, Tarun Chakravarty, Hasan Jilaihawi, Jean-Michel Paradis, Fabio S de Brito, Sergio J Cánovas, Asim N Cheema, Peter P de Jaegere, Raquel del Valle, Paul T L Chiam, Raúl Moreno, Gonzalo Pradas, Marc Ruel, Jorge Salgado-Fernández, Rogerio Sarmento-Leite, Hadi D Toeg, James L Velianou, Alan Zajarias, Vasilis Babaliaros, Fernando Cura, Antonio E Dager, Ganesh Manoharan, Stamatios Lerakis, Augusto D Pichard, Sam Radhakrishnan, Marco Antonio Perin, Eric Dumont, Eric Larose, Sergio G Pasian, Luis Nombela-Franco, Marina Urena, E Murat Tuzcu, Martin B Leon, Ignacio J Amat-Santos, Jonathon Leipsic, and Josep Rodés-Cabau.
• Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.
• J. Am. Coll. Cardiol. 2013 Oct 22;62(17):1552-62.

ObjectivesThis study sought to evaluate the main baseline and procedural characteristics, management, and clinical outcomes of patients from a large cohort of patients undergoing transcatheter aortic valve implantation (TAVI) who suffered coronary obstruction (CO).BackgroundVery little data exist on CO following TAVI.MethodsThis multicenter registry included 44 patients who suffered symptomatic CO following TAVI of 6,688 patients (0.66%). Pre-TAVI computed tomography data was available in 28 CO patients and in a control group of 345 patients (comparisons were performed including all patients and a cohort matched 1:1 by age, sex, previous coronary artery bypass graft, transcatheter valve type, and size).ResultsBaseline and procedural variables associated with CO were older age (p < 0.001), female sex (p < 0.001), no previous coronary artery bypass graft (p = 0.043), the use of a balloon-expandable valve (p = 0.023), and previous surgical aortic bioprosthesis (p = 0.045). The left coronary artery was the most commonly involved (88.6%). The mean left coronary artery ostia height and sinus of Valsalva diameters were lower in patients with obstruction than in control subjects (10.6 ± 2.1 mm vs. 13.4 ± 2.1 mm, p < 0.001; 28.1 ± 3.8 mm vs. 31.9 ± 4.1 mm, p < 0.001). Differences between groups remained significant after the case-matched analysis (p < 0.001 for coronary height; p = 0.01 for sinus of Valsalva diameter). Most patients presented with persistent severe hypotension (68.2%) and electrocardiographic changes (56.8%). Percutaneous coronary intervention was attempted in 75% of the cases and was successful in 81.8%. Thirty-day mortality was 40.9%. After a median follow-up of 12 (2 to 18) months, the cumulative mortality rate was 45.5%, and there were no cases of stent thrombosis or reintervention.ConclusionsSymptomatic CO following TAVI was a rare but life-threatening complication that occurred more frequently in women, in patients receiving a balloon-expandable valve, and in those with a previous surgical bioprosthesis. Lower-lying coronary ostium and shallow sinus of Valsalva were associated anatomic factors, and despite successful treatment, acute and late mortality remained very high, highlighting the importance of anticipating and preventing the occurrence of this complication.Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

50 keywords...

hide…